Stryker Corporation 10-Q Summary: Q1 2007
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2007. Stryker Corporation is a leading medical technology company operating in two primary segments: Orthopaedic Implants and MedSurg Equipment. The company also provides physical therapy services. Domestic sales accounted for 66% of total revenue, while international sales accounted for 34%.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Sales | $1,489.3 million | $1,320.9 million |
| Gross Profit | $992.6 million (66.6% margin) | $868.0 million (65.7% margin) |
| Operating Income | $325.3 million | $222.1 million |
| Net Earnings | $243.5 million | $147.5 million |
| Diluted EPS | $0.59 | $0.36 |
| Cash from Operations | $152.7 million | $20.7 million |
| Cash & Equivalents | $294.3 million | $416.6 million (Dec 2006) |
| Marketable Securities | $1,171.9 million | $998.2 million (Dec 2006) |
| Total Debt | $15.2 million | $14.8 million (Dec 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% year-over-year, driven by an 11% increase in unit volume and product mix, with a 2% favorable impact from foreign currency exchange rates.
- Profitability: Net earnings surged 65% to $243.5 million. This growth is partially attributable to the absence of a $52.7 million "purchased in-process research and development" charge recorded in Q1 2006 related to the Sightline acquisition.
- Adjusted Performance: On an adjusted basis (excluding the 2006 charge), net earnings increased 22% and diluted EPS increased 20% compared to the prior year.
- Segment Performance: Orthopaedic Implants sales grew 13% (10% constant currency), while MedSurg Equipment sales grew 15% (14% constant currency). Physical Therapy Services declined 5%.
- Working Capital: Working capital increased by $453.9 million to $2,636.7 million, aided by a $179.2 million reclassification of income tax liabilities from current to non-current.
Guidance, Outlook, and Risks
- 2007 Outlook: Management projects diluted net earnings per share of approximately $2.42 for 2007, representing a 28% increase over 2006. On an adjusted basis, this represents a 20% increase.
- Sales Forecast: The company anticipates constant currency net sales growth of 11% to 13% for 2007. Foreign currency is expected to provide a favorable impact of 0.5% to 1.5% for the full year.
- Accounting Changes: The company adopted FASB Interpretation No. 48 on January 1, 2007, resulting in a $7.6 million reduction to retained earnings (net of tax) due to increased interest accruals on unresolved tax positions.
- Legal Contingencies: The company is cooperating with Department of Justice investigations regarding billing practices (Physiotherapy Associates), consulting contracts with surgeons, and potential antitrust violations related to orthopaedic implants. No material losses are anticipated beyond amounts already provided.
- Risks: Key risks include pricing pressures, regulatory delays (FDA), reimbursement changes, and foreign exchange fluctuations.
Investor Verification Checklist
- Verify the sustainability of the 13% sales growth rate, specifically the contribution of new product launches (e.g., X3 Polyethylene, Triathlon knee system) versus organic demand.
- Monitor the status of the Department of Justice investigations and potential financial impact of settlements or penalties.
- Assess the impact of the Sightline acquisition milestone payments (up to $90 million) on future earnings once targets are met.
- Review the company's ability to maintain gross margins amidst potential pricing pressures and higher royalty costs.
- Confirm the timeline for the commercialization of flexible endoscope technologies acquired from Sightline.